MAFLD biomarkers: a review

The identification of high-risk MAFLD patients is paramount. Liver biopsy is still considered the gold standard for the assessment of patients with MAFLD. The search for noninvasive biomarkers .....
PUBLISHED IN: J Clin Transl Hepatol 2022

Commentary

The identification of high-risk MAFLD patients is paramount. Liver biopsy is still considered the gold standard for the assessment of patients with MAFLD. The search for noninvasive biomarkers for MAFLD remains an area of intensive research.

In this review, J. Alharthi et al. (Westmead Hospital and University of Sydney, Australia, and Faculty of Science, Taif University, Saudi Arabia) provide an update on the current and future biomarkers of MAFLD

Share the article
Dr. D. Beard

Dr. D. Beard

Articles: 189

Leave a Reply

Your email address will not be published.

SUBSCRIBE & FOLLOW US

SUBSCRIBE TO OUR MONTHLY NEWSLETTER TO GET THE LATEST UPDATES